fda warning bpc-157 peptide not approved safety concerns BPC 157 Banned: Key Facts on the Latest Decision Federal health advisers are meeting

Homocysteine rises when there is not enough B12 in the cell fluid to support methylation, an important process where a methyl group is added to all sorts of molecules in the cell

NAD+ vs NMN vs NR (and IV vs SubQ) NAD+ Delivery Comparison Feature Mechanism NAD+ Injection (SubQ) Direct coenzyme delivery NAD+ Infusion (IV) Direct coenzyme delivery Oral NMN NAD+ precursor (converted in vivo) Oral NR (Niagen) NAD+ precursor (converted in vivo) Feature Typical research-planning dose NAD+ Injection (SubQ) 50-100 mg, 2-3x/week NAD+ Infusion (IV) 250-1,000 mg per session Oral NMN 300-600 mg/day Oral NR (Niagen) 300-1,000 mg/day Feature Speed to systemic NAD+ rise NAD+ Injection (SubQ) Hours NAD+ Infusion (IV) Minutes to hours Oral NMN Days to weeks Oral NR (Niagen) Days to weeks Feature Strongest human evidence NAD+ Injection (SubQ) Limited NAD+ Infusion (IV) Pilot PK and historical case reports Oral NMN Growing RCT base Oral NR (Niagen) Strongest RCT base Feature Convenience NAD+ Injection (SubQ) At-home injection technique required NAD+ Infusion (IV) Clinic visit, 2-4 hour infusion Oral NMN Daily oral capsule Oral NR (Niagen) Daily oral capsule Feature Regulatory status NAD+ Injection (SubQ) Not FDA-approved

It has been tested in six clinical trials involving around 900 test subjects and has been determined by an appropriately qualified GRAS panel of experts to be Generally Recognized As Safe (GRAS) under conditions of intended uses of AOD9604 in foods [1]

Results showed: Significantly faster healing compared to controls Improved biomechanical properties of healed tendons Better collagen fiber organization Enhanced tensile strength Follow-up studies confirmed these findings and demonstrated that BPC-157 stimulated tendon cell (tenocyte) proliferation and migration in vitro